Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit trialsjournal.biomedcentral.com/covid-19 for more information.

Page 4 of 4

  1. To evaluate the safety of therapeutic plasma exchange (TPE) in adult patients with serious/life-threatening COVID-19 requiring intensive care unit (ICU) admission, and associated 28-day mortality. Serious and ...

    Authors: Fahad Faqihi, Abdulrahman Alharthy, Mohammed Alodat, Daood Asad, Waleed Aletreby, Demetrios J. Kutsogiannis, Peter G. Brindley and Dimitrios Karakitsos

    Citation: Trials 2020 21:506

    Content type: Letter

    Published on:

  2. To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currentl...

    Authors: José Meneses Calderón, Hugo Mendieta Zerón and Srivatsan Padmanabhan

    Citation: Trials 2020 21:504

    Content type: Letter

    Published on:

  3. The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.

    Authors: Christina M. Eckhardt, Matthew J. Cummings, Kartik N. Rajagopalan, Sarah Borden, Zachary C. Bitan, Allison Wolf, Alex Kantor, Thomas Briese, Benjamin J. Meyer, Samuel D. Jacobson, Dawn Scotto, Nischay Mishra, Neena M. Philip, Brie A. Stotler, Joseph Schwartz, Beth Shaz…

    Citation: Trials 2020 21:499

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:927

    The Correction to this article has been published in Trials 2020 21:536

  4. The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of p...

    Authors: Carlos Chaccour, Paula Ruiz-Castillo, Mary-Ann Richardson, Gemma Moncunill, Aina Casellas, Francisco Carmona-Torre, Miriam Giráldez, Juana Schwartz Mota, José Ramón Yuste, José Ramón Azanza, Miriam Fernández, Gabriel Reina, Carlota Dobaño, Joe Brew, Belen Sadaba, Felix Hammann…

    Citation: Trials 2020 21:498

    Content type: Letter

    Published on:

  5. Patients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very...

    Authors: Chi Zhang, Jiawen Li, Zhao Wu, He Wang, Chengli Que, Hong Zhao and Guiqiang Wang

    Citation: Trials 2020 21:495

    Content type: Letter

    Published on:

  6. The hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeosta...

    Authors: Cedric Bosteels, Bastiaan Maes, Karel Van Damme, Elisabeth De Leeuw, Jozefien Declercq, Anja Delporte, Bénédicte Demeyere, Stéfanie Vermeersch, Marnik Vuylsteke, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Stefaan Vandecasteele, Isabelle Peene…

    Citation: Trials 2020 21:491

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:554

  7. Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reduc...

    Authors: Nooshin Dalili, Alireza Kashefizadeh, Mohsen Nafar, Fatemeh Poorrezagholi, Ahmad Firouzan, Fariba Samadian, Shiva Samavat, Shadi Ziaie and Somayeh Fatemizadeh

    Citation: Trials 2020 21:489

    Content type: Letter

    Published on:

  8. A variety of possible mechanisms can make the nucleic acid test of patients who meet the discharge conditions positive again, including reinfection, reactivation of the original virus, lack of strict discharge...

    Authors: Jiawen Li, Chi Zhang, Zhao Wu, Guiqiang Wang and Hong Zhao

    Citation: Trials 2020 21:488

    Content type: Letter

    Published on:

  9. The hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus disease 2019 (Covid-19) is safe and will accelerate the virological clearance rate for p...

    Authors: Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø and Olav Dalgard

    Citation: Trials 2020 21:485

    Content type: Letter

    Published on:

  10. The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination.

    Authors: Thijs ten Doesschate, Simone J. C. F. M. Moorlag, Thomas W. van der Vaart, Esther Taks, Priya Debisarun, Jaap ten Oever, Chantal P. Bleeker-Rovers, Patricia Bruijning Verhagen, Arief Lalmohamed, Rob ter Heine, Reinout van Crevel, Janneke van de Wijgert, Axel B. Janssen, Marc J. Bonten, Cornelis H. van Werkhoven and Mihai G. Netea

    Citation: Trials 2020 21:481

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:555

  11. Objective: To undertake a pilot, feasibility RCT of umbilical cord blood derived cell therapy for treatment of adult patients infected with SARS-CoV-2 virus related moderate-to-severe pneumonia to prevent prog...

    Authors: Atul Malhotra, David Ernest, Benjamin A. Rogers, David Haylock, Ashalyn Watt, Guy Moeneclaey and Graham Jenkin

    Citation: Trials 2020 21:474

    Content type: Letter

    Published on:

  12. Citation: Trials 2020 21:475

    Content type: Letter

    Published on:

  13. We will investigate the effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen in COVID-19 in patients that have tested positive and are moderately to severely ill.

    Authors: Seyed Sina Naghibi Irvani, Maryam Golmohammadi, Mohamad Amin Pourhoseingholi, Shervin Shokouhi and Ilad Alavi Darazam

    Citation: Trials 2020 21:473

    Content type: Letter

    Published on:

  14. SARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhib...

    Authors: Antonio Cuadrado-Lavín, José Manuel Olmos, José Manuel Cifrian, Teresa Gimenez, Marco Antonio Gandarillas, Mar García-Saiz, Maria Henar Rebollo, Victor Martínez-Taboada, Marcos López-Hoyos, María Carmen Fariñas and Javier Crespo

    Citation: Trials 2020 21:472

    Content type: Letter

    Published on:

  15. SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Obj...

    Authors: Jonathan Rilinger, Winfried V. Kern, Daniel Duerschmied, Alexander Supady, Christoph Bode, Dawid L. Staudacher and Tobias Wengenmayer

    Citation: Trials 2020 21:470

    Content type: Letter

    Published on:

  16. Entertainment-education (E-E) media can improve behavioral intent toward health-related practices. In the era of COVID-19, millions of people can be reached by E-E media without requiring any physical contact....

    Authors: Alain Vandormael, Maya Adam, Merlin Greuel and Till Bärnighausen

    Citation: Trials 2020 21:469

    Content type: Letter

    Published on:

    The Update to this article has been published in Trials 2020 21:1025

  17. The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6, IL-6 receptor and IL-1 versus standard of care on blood oxygenation and systemic cytokine rele...

    Authors: Bastiaan Maes, Cedric Bosteels, Elisabeth De Leeuw, Jozefien Declercq, Karel Van Damme, Anja Delporte, Bénédicte Demeyere, Stéfanie Vermeersch, Marnik Vuylsteke, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Stefaan Vandecasteele, Isabelle Peene…

    Citation: Trials 2020 21:468

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:556

  18. Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals

    Authors: Reihaneh Pirjani, Tahereh Soori, Ahmad Reza Dehpour, Mahdi Sepidarkish, Ashraf Moini, Arshia Shizarpour and Razieh Mohammad Jafari

    Citation: Trials 2020 21:467

    Content type: Letter

    Published on:

  19. Primary objective: to evaluate the efficacy of melatonin as a prophylactic treatment on prevention of symptomatic SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure.

    Authors: Irene García García, Miguel Rodriguez-Rubio, Amelia Rodríguez Mariblanca, Lucía Martínez de Soto, Lucía Díaz García, Jaime Monserrat Villatoro, Javier Queiruga Parada, Enrique Seco Meseguer, María J. Rosales, Juan González, José R. Arribas, Antonio J. Carcas, Pedro de la Oliva and Alberto M. Borobia

    Citation: Trials 2020 21:466

    Content type: Letter

    Published on:

  20. The primary objective of the study is to assess the safety of a single intravenous infusion of Mesenchymal Stromal Cells (MSCs) in patients with Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. Seco...

    Authors: Ellen Gorman, Manu Shankar-Hari, Phil Hopkins, William S. Tunnicliffe, Gavin D. Perkins, Jonathan Silversides, Peter McGuigan, Colette Jackson, Roisin Boyle, Jamie McFerran, Cliona McDowell, Christina Campbell, Margaret McFarland, Jon Smythe, Jacqui Thompson, Barry Williams…

    Citation: Trials 2020 21:462

    Content type: Letter

    Published on:

  21. Citation: Trials 2020 21:430

    Content type: Letter

    Published on:

  22. Efficacy of conventional treatment plus the complementary therapy Liu-zi-jue (a mind-body exercise) to treat patients with mild COVID-19.

    Authors: Shuaipan Zhang, Zhizhen Lv, Qingguang Zhu, Wuquan Sun, Fei Yao, Lei Fang, Yanbin Cheng, Zhiwei Wu and Min Fang

    Citation: Trials 2020 21:416

    Content type: Letter

    Published on:

  23. This study aims to assess the effectiveness of delivering Solution Focused Brief Therapy (SFBT) through telecommunication with a group of adolescents who present anxiety symptoms during the COVID-19 outbreak. ...

    Authors: Shitao Chen

    Citation: Trials 2020 21:402

    Content type: Letter

    Published on: